Truist lowered the firm’s price target on Autolus Therapeutics (AUTL) to $8 from $10 and keeps a Buy rating on the shares. The company pre-announced Q4 sales of $24M, in line with consensus, but guidance for 2026 AUCATZYL sales of $120M-$135M was below consensus, causing shares to decline, the analyst tells investors in a research note. Investor focus in 2026 is expected to shift toward cost of goods, which have outpaced sales to date, with margin improvement driven by volume scale and manufacturing efficiencies, likely becoming more evident in the second half of 2026, the firm added.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUTL:
- Autolus: Short-Term Revenue Miss, Long-Term Blockbuster Potential Supports Buy Rating
- Maintaining Buy on Autolus: Solid Aucatzyl Growth and Extended Cash Runway Support Attractive Risk‑Reward Despite Lowered Targets
- Autolus Therapeutics price target lowered to $10 from $11 at Needham
- Autolus issues 2025 AUCATZYL results and 2026 outlook
- Autolus Therapeutics sees Q4 AUCATZYL revenue of $24M